Roles of microRNA-124a and microRNA-30d in breast cancer patients with type 2 diabetes mellitus

Tumor Biology

Volumn 37, Issue 8, 2016, Pages 11057-11063

  Zhang, Shu ^a   Guo, Ling Ji ^a   Zhang, Gang ^a   Wang, Ling Li ^a   Hao, Shuai ^a   Gao, Bo ^a   Jiang, Yan ^a   Tian, Wu Guo ^a   Cao, Xian E ^a   Luo, Dong Lin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Estradiol; Glycosylated hemoglobin; Insulin resistance index; MiR 124a; MiR 30d; Type 2 diabetes mellitus

Indexed keywords

ESTRADIOL; HEMOGLOBIN; HEMOGLOBIN A1C; MICRORNA; MICRORNA 124A; MICRORNA 30D; UNCLASSIFIED DRUG; GLYCOSYLATED HEMOGLOBIN; INSULIN; MIRN124 MICRORNA, HUMAN; MIRN30 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; INSULIN RESISTANCE INDEX; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL PARAMETERS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; BLOOD; BREAST TUMOR; COMPLICATION; GENETICS; INSULIN RESISTANCE; MIDDLE AGED;

ADULT; AGED; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84958778400     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4981-6     Document Type: Article

References (31)

1. Wang RJ, Lu LJ, Jin LB, Li HY, Ren GS, Wu KN, et al. Clinicopathologic features of breast cancer patients with type 2 diabetes mellitus in southwest of china. Med Oncol. 2014;31(1):788.
2. Pan B, Ren H, Ma Y, Liu D, Yu B, Ji L, et al. High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int J Cancer. 2012;131(1):70–82.
3. Liu X, Hemminki K, Forsti A, Sundquist K, Sundquist J, Ji J. Cancer risk in patients with type 2 diabetes mellitus and their relatives. Int J Cancer. 2015;137(4):903–10.
4. Luo J, Virnig B, Hendryx M, Wen S, Chelebowski R, Chen C, et al. Diabetes, diabetes treatment and breast cancer prognosis. Breast Cancer Res Treat. 2014;148(1):153–62.
5. Kaplan MA, Pekkolay Z, Kucukoner M, Inal A, Urakci Z, Ertugrul H, et al. Type 2 diabetes mellitus and prognosis in early stage breast cancer women. Med Oncol. 2012;29(3):1576–80.
6. He DE, Bai JW, Liu J, Du CW, Huang WH, Zhang GJ. Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus. Mol Clin Oncol. 2015;3(3):607–12.
7. Li X, Du N, Zhang Q, Li J, Chen X, Liu X, et al. MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy. Cell Death Dis. 2014;5:e1479.
8. Trehoux S, Lahdaoui F, Delpu Y, Renaud F, Leteurtre E, Torrisani J, et al. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim Biophys Acta. 2015;1853(10):2392–403.
9. Li J, Li L, Li Z, Gong G, Chen P, Liu H, et al. The role of miR-205 in the VEGF-mediated promotion of human ovarian cancer cell invasion. Gynecol Oncol. 2015;137(1):125–33.
10. Kim S, Rhee JK, Yoo HJ, Lee HJ, Lee EJ, Lee JW, et al. Bioinformatic and metabolomic analysis reveals miR-155 regulates thiamine level in breast cancer. Cancer Lett. 2015;357(2):488–97.
11. Chen X, He D, Dong XD, Dong F, Wang J, Wang L, et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54(3):2248–56.
12. Sebastiani G, Po A, Miele E, Ventriglia G, Ceccarelli E, Bugliani M, et al. MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. Acta Diabetol. 2015;52(3):523–30.
13. Yu H, Lin X, Wang F, Zhang B, Wang W, Shi H, et al. Proliferation inhibition and the underlying molecular mechanisms of microRNA-30d in renal carcinoma cells. Oncol Lett. 2014;7(3):799–804.
14. Zhao X, Mohan R, Ozcan S, Tang X. MicroRNA-30d induces insulin transcription factor mafa and insulin production by targeting mitogen-activated protein 4 kinase 4 (map4k4) in pancreatic beta-cells. J Biol Chem. 2012;287(37):31155–64.
15. PN M. World medical association publishes the revised Declaration of Helsinki. Natl Med J India. 2014;27(1):56.
16. Lou M, Luo P, Tang R, Peng Y, Yu S, Huang W, et al. Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients. BMC Endocr Disord. 2015;15:9.
17. Pala L, Barbaro V, Dicembrini I, Rotella CM. The therapy of insulin resistance in other diseases besides type 2 diabetes. Eat Weight Disord. 2014;19(3):275–83.
18. Okuno A, Kaji N, Takahashi A, Nagakubo D, Ohno-Ichiki K, Shirai M, et al. Role of insulin resistance in the pathogenesis and development of type 2 diabetes in wbn/kob-lepr(fa) rats. J Vet Med Sci. 2013;75(12):1557–61.
19. Mizokami-Stout K, Cree-Green M, Nadeau KJ. Insulin resistance in type 2 diabetic youth. Curr Opin Endocrinol Diabetes Obes. 2012;19(4):255–62.
20. Liu A, Kushida CA, Reaven GM. Habitual shortened sleep and insulin resistance: an independent relationship in obese individuals. Metabolism. 2013;62(11):1553–6.
21. Yoon SR, Lee JH, Na GY, Seo YJ, Han S, Shin MJ, et al. Glycated hemoglobin is a better predictor than fasting glucose for cardiometabolic risk in non-diabetic Korean women. Clin Nutr Res. 2015;4(2):97–103.
22. Incani M, Sentinelli F, Perra L, Pani MG, Porcu M, Lenzi A, et al. Glycated hemoglobin for the diagnosis of diabetes and prediabetes: diagnostic impact on obese and lean subjects, and phenotypic characterization. J Diabetes Investig. 2015;6(1):44–50.
23. Joshu CE, Prizment AE, Dluzniewski PJ, Menke A, Folsom AR, Coresh J, et al. Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) study, 1990–2006. Int J Cancer. 2012;131(7):1667–77.
24. Li XL, Li JJ, Guo YL, Zhu CG, Xu RX, Li S, et al. Relationship of glycated hemoglobin levels with myocardial injury following elective percutaneous coronary intervention in patients with type 2 diabetes mellitus. PLoS One. 2014;9(7), e101719.
25. Su HI, Sue LY, Flatt SW, Natarajan L, Patterson RE, Pierce JP. Endogenous estradiol is not associated with poor physical health in postmenopausal breast cancer survivors. J Womens Health (Larchmt). 2013;22(12):1043–8.
26. Kim JY, Han W, Moon HG, Ahn SK, Kim J, Lee JW, et al. Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer. BMC Cancer. 2013;13:503.
27. Chalasani P, Stopeck A, Clarke K, Livingston R. A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancer. Oncologist. 2014;19(11):1127–8.
28. Ben Gacem R, Ben Abdelkrim O, Ziadi S, Ben Dhiab M, Trimeche M. Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease. Tumour Biol. 2014;35(5):4047–56.
29. Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y, et al. Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget. 2012;3(11):1455–71.
30. Ling HY, Hu B, Hu XB, Zhong J, Feng SD, Qin L, et al. MiRNA-21 reverses high glucose and high insulin induced insulin resistance in 3t3-l1 adipocytes through targeting phosphatase and tensin homologue. Exp Clin Endocrinol Diabetes. 2012;120(9):553–9.
31. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (bcrp/abcg2) in drug transport—an update. AAPS J. 2015;17(1):65–82.